**Risk factors for the development of neonatal sepsis in a neonatal intensive care unit of a tertiary care hospital of Nepal**

Sulochana Manandhar 1,2, Puja Amatya 3, Imran Ansari 3, Niva Joshi 1, Nhukesh Maharjan 1,

Sabina Dongol 1, Buddha Basnyat 1, Sameer M. Dixit 4, Stephen Baker 5 and Abhilasha Karkey 1\*

1 Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal

2 Centre for Tropical Medicine and Global Health, Medical sciences division, Nuffield Department of Medicine, University of Oxford, Linacre College, Oxford, UK

3 Department of Pediatrics, Patan Academy of Health Sciences, Patan Hospital, Kathmandu, Nepal

4 Center for Molecular Dynamics Nepal, Kathmandu, Nepal

5 Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) Department of Medicine, University of Cambridge, Cambridge, UK

**\*Correspondence**

Dr Abhilasha Karkey

akarkey@oucru.org

**Additional file 2 Empirical antimicrobial therapy and duration of antimicrobials used for therapeutic management of neonatal sepsis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Antimicrobials | Protocol on empirical antimicrobial therapy | Cases | | Days of use | |
| **Number** | **%** | **Median** | **IQR** |
| Ampicillin | first line | 129 | 90.8 | 6 | 4-8 |
| Amikacin | first line | 128 | 90.2 | 6 | 4-8 |
| Cloxacillin | first line\* | 6 | 4.2 | 3.5 | 3-7.8 |
| Cefotaxime | first line\*\* | 80 | 56.3 | 3 | 2-6.3 |
| Chloramphenicol | second line | 57 | 40.1 | 6 | 3-10 |
| Ofloxacin | second line | 60 | 42.3 | 6.5 | 3-10 |
| Meropenem | third line# | 37 | 26.1 | 7 | 7-11 |
| Colistin | third line# | 24 | 16.9 | 10 | 6-12.3 |
| Clindamycin | third line# | 19 | 13.4 | 6 | 3-9.5 |
| Piperacillin-Tazobactam | third line# | 18 | 12.7 | 7 | 4.8-9.8 |
| Fluconazole | third line# | 17 | 11.9 | 7 | 6-12 |
| Vancomycin | third line# | 12 | 8.5 | 7 | 5.3-8.5 |

\*added if Gram positive cocci suspected

\*\*added if meningitis suspected

# the third line empirical therapy is constituted of combination of meropenem and ofloxacin; or piperacillin/tazobacam and ofloxacin; or meropenem and vancomycin/linezolid; or cefepime and pipercillin/tazobactam; or meropenem and colistin